Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs

Research output: Contribution to journal › Journal article › peer-review

Standard

Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. / Eedara, Basanth Babu; Tucker, Ian G.; Zujovic, Zoran D.; Rades, Thomas; Price, Jason R.; Das, Shyamal C.

In: European Journal of Pharmaceutical Sciences, Vol. 136, 104961, 2019.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Eedara, BB, Tucker, IG, Zujovic, ZD, Rades, T, Price, JR & Das, SC 2019, 'Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs', European Journal of Pharmaceutical Sciences, vol. 136, 104961. https://doi.org/10.1016/j.ejps.2019.104961

APA

Eedara, B. B., Tucker, I. G., Zujovic, Z. D., Rades, T., Price, J. R., & Das, S. C. (2019). Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. European Journal of Pharmaceutical Sciences, 136, [104961]. https://doi.org/10.1016/j.ejps.2019.104961

Vancouver

Eedara BB, Tucker IG, Zujovic ZD, Rades T, Price JR, Das SC. Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. European Journal of Pharmaceutical Sciences. 2019;136. 104961. https://doi.org/10.1016/j.ejps.2019.104961

Author

Eedara, Basanth Babu ; Tucker, Ian G. ; Zujovic, Zoran D. ; Rades, Thomas ; Price, Jason R. ; Das, Shyamal C. / Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. In: European Journal of Pharmaceutical Sciences. 2019 ; Vol. 136.

Bibtex

@article{1e4d22f8f4184aad9a6af7567caae55e,
title = "Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs",
abstract = "A crystalline adduct of the anti-tubercular drug, moxifloxacin and trans-cinnamic acid (1:1 molar ratio (MCA1:1)) was prepared to prolong the residence time of the drug in the lungs by reducing its solubility and dissolution rate. Whether the adduct is a salt or cocrystal has not been unequivocally determined. Equilibrium solubility and intrinsic dissolution rate measurements for the adduct (MCA1:1) in phosphate buffered saline (PBS, pH 7.4) revealed a significant decrease in the solubility of moxifloxacin (from 17.68 ± 0.85 mg mL−1 to 6.10 ± 0.05 mg mL−1) and intrinsic dissolution rate (from 0.47 ± 0.04 mg cm−2 min−1 to 0.14 ± 0.03 mg cm−2 min−1) compared to the supplied moxifloxacin. The aerosolization behaviour of the adduct from an inhaler device, Aerolizer{\textregistered}, using a Next Generation Impactor showed a fine particle fraction of 30.4 ± 1.2%. The dissolution behaviour of the fine particle dose of respirable particles collected was assessed in a small volume of stationary mucus fluid using a custom-made dissolution apparatus. The respirable adduct particles showed a lower dissolution (microscopic observation) and permeation compared to the supplied moxifloxacin. The crystalline adduct MCA1:1 has a lower solubility and dissolution rate than moxifloxacin and could improve the local residence time and therapeutic action of moxifloxacin in the lungs.",
keywords = "Crystalline adduct, Dissolution, Moxifloxacin, Respirable particle, Solubility, Trans-cinnamic acid, Tuberculosis",
author = "Eedara, {Basanth Babu} and Tucker, {Ian G.} and Zujovic, {Zoran D.} and Thomas Rades and Price, {Jason R.} and Das, {Shyamal C.}",
year = "2019",
doi = "10.1016/j.ejps.2019.104961",
language = "English",
volume = "136",
journal = "Norvegica Pharmaceutica Acta",
issn = "0928-0987",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs

AU - Eedara, Basanth Babu

AU - Tucker, Ian G.

AU - Zujovic, Zoran D.

AU - Rades, Thomas

AU - Price, Jason R.

AU - Das, Shyamal C.

PY - 2019

Y1 - 2019

N2 - A crystalline adduct of the anti-tubercular drug, moxifloxacin and trans-cinnamic acid (1:1 molar ratio (MCA1:1)) was prepared to prolong the residence time of the drug in the lungs by reducing its solubility and dissolution rate. Whether the adduct is a salt or cocrystal has not been unequivocally determined. Equilibrium solubility and intrinsic dissolution rate measurements for the adduct (MCA1:1) in phosphate buffered saline (PBS, pH 7.4) revealed a significant decrease in the solubility of moxifloxacin (from 17.68 ± 0.85 mg mL−1 to 6.10 ± 0.05 mg mL−1) and intrinsic dissolution rate (from 0.47 ± 0.04 mg cm−2 min−1 to 0.14 ± 0.03 mg cm−2 min−1) compared to the supplied moxifloxacin. The aerosolization behaviour of the adduct from an inhaler device, Aerolizer®, using a Next Generation Impactor showed a fine particle fraction of 30.4 ± 1.2%. The dissolution behaviour of the fine particle dose of respirable particles collected was assessed in a small volume of stationary mucus fluid using a custom-made dissolution apparatus. The respirable adduct particles showed a lower dissolution (microscopic observation) and permeation compared to the supplied moxifloxacin. The crystalline adduct MCA1:1 has a lower solubility and dissolution rate than moxifloxacin and could improve the local residence time and therapeutic action of moxifloxacin in the lungs.

AB - A crystalline adduct of the anti-tubercular drug, moxifloxacin and trans-cinnamic acid (1:1 molar ratio (MCA1:1)) was prepared to prolong the residence time of the drug in the lungs by reducing its solubility and dissolution rate. Whether the adduct is a salt or cocrystal has not been unequivocally determined. Equilibrium solubility and intrinsic dissolution rate measurements for the adduct (MCA1:1) in phosphate buffered saline (PBS, pH 7.4) revealed a significant decrease in the solubility of moxifloxacin (from 17.68 ± 0.85 mg mL−1 to 6.10 ± 0.05 mg mL−1) and intrinsic dissolution rate (from 0.47 ± 0.04 mg cm−2 min−1 to 0.14 ± 0.03 mg cm−2 min−1) compared to the supplied moxifloxacin. The aerosolization behaviour of the adduct from an inhaler device, Aerolizer®, using a Next Generation Impactor showed a fine particle fraction of 30.4 ± 1.2%. The dissolution behaviour of the fine particle dose of respirable particles collected was assessed in a small volume of stationary mucus fluid using a custom-made dissolution apparatus. The respirable adduct particles showed a lower dissolution (microscopic observation) and permeation compared to the supplied moxifloxacin. The crystalline adduct MCA1:1 has a lower solubility and dissolution rate than moxifloxacin and could improve the local residence time and therapeutic action of moxifloxacin in the lungs.

KW - Crystalline adduct

KW - Dissolution

KW - Moxifloxacin

KW - Respirable particle

KW - Solubility

KW - Trans-cinnamic acid

KW - Tuberculosis

U2 - 10.1016/j.ejps.2019.104961

DO - 10.1016/j.ejps.2019.104961

M3 - Journal article

C2 - 31220546

AN - SCOPUS:85067616135

VL - 136

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

SN - 0928-0987

M1 - 104961

ER -

ID: 241099472